文献速递糖尿病

慢性肾脏病合并2型糖尿病的联合治疗:综述与实践指导

Combination treatment for the management of chronic kidney disease and type 2 diabetes: a review and practical guidance.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

本综述总结了RASi、SGLT2i、nsMRA和GLP-1RA联合用于CKD合并T2D的循证证据,提出加速实施四联治疗的实践算法,并讨论提高联合治疗采纳率的策略。RCT支持在标准治疗基础上加用各药物,多部指南认可联合治疗,但最佳启动顺序、时机及副作用管理尚不明确。

要点

  • SGLT2i、nsMRA和GLP-1RA通过独立机制提供早期心肾保护,可联合使用。
  • RCT支持在标准治疗基础上加用各药物,多部指南认可联合治疗。
  • 最佳启动顺序、时机及副作用管理不确定,限制联合治疗推广。

核心结论

  • 当前证据支持在CKD合并T2D患者中使用联合指南导向药物治疗(GDMT)。
  • 提出的联合治疗算法可能克服临床惰性,在高危CKD合并T2D患者中实现更大的心肾风险降低。

研究设计与样本

  • 综述:检索PubMed从建库至当前,聚焦临床指南、随机对照试验(RCT),必要时纳入大型观察性研究。

主要发现

  • SGLT2i、nsMRA和GLP-1RA通过独立机制提供早期心血管和肾脏保护,允许联合使用。
  • RCT支持在「标准治疗」基础上加用每种药物,多部临床指南认可联合治疗。
  • 最佳用药启动顺序和时机以及治疗相关副作用的管理方法仍不确定。

临床怎么用

  • 提出的联合治疗算法可能帮助克服临床惰性,加速四联治疗的实施。
  • 在高危CKD合并T2D患者中,联合GDMT可实现更大的心肾风险降低。

局限性

  • 最佳用药启动顺序和时机以及治疗相关副作用的管理方法仍不确定,限制联合治疗的采纳。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Renin-angiotensin system inhibitors (RASi), sodium glucose cotransporter-2 inhibitors (SGLT2i), non-steroidal mineralocorticoid receptor antagonists (nsMRA), and glucagon-like peptide-1 receptor agonists (GLP-1RA) are key components of guideline-directed medical treatments (GDMT) for chronic kidney disease (CKD) with type 2 diabetes (T2D). However, the combined use of these medications remains uncommon in clinical practice, in part, due to the absence of specific guidance on implementing combination treatment. Herein, we aim to (1) summarize the evidence supporting combination GDMT in CKD with T2D, (2) propose a practical algorithm to guide the accelerated implementation of quadruple treatment, and (3) discuss strategies to improve the uptake of combination treatment. EVIDENCE ACQUISITION: We searched PubMed from inception to present for English-speaking studies using the search terms: "renin-angiotensin system inhibitor," "sodium glucose cotransporter-2 inhibitor," "nonsteroidal mineralocorticoid receptor antagonist," "glucagon-like peptide-1 receptor agonist," and "diabetes." We focused on clinical guidelines, randomized controlled trials (RCTs), and, if necessary, large observational studies. EVIDENCE SYNTHESIS: SGLT2i, nsMRA, and GLP-1RA confer early cardiovascular and kidney protection through independent mechanisms, allowing them to be combined. RCTs support the use of each agent on top of "standard care," and multiple clinical guidelines endorse combination treatment. However, the optimal order and timing for medication initiation and the approach to managing treatment-related side effects remain uncertain, thereby limiting the uptake of combination treatment. CONCLUSION: Current evidence supports the use of combination GDMT in CKD with T2D. We propose a combination treatment algorithm that may combat clinical inertia and achieve greater cardiorenal risk reduction in high-risk patients with CKD and T2D.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Mohsen M, Yi TW, Faruque L, et al. Combination treatment for the management of chronic kidney disease and type 2 diabetes: a review and practical guidance. J Clin Endocrinol Metab. 2026. PMID: 41973867. doi:10.1210/clinem/dgag163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。